The FDA dinged generics maker Cipla’s quality unit for several lapses, including failing to properly investigate batch discrepancies or the impact of power outages on drug product, during a Feb. 6-17 inspection of the company’s Madhya, Pradesh, India plant.
Source: Drug Industry Daily